Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN versus CORDRAN N.
CORDRAN vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Apply a thin layer to the affected skin areas once or twice daily. For CORDRAN Tape, apply tape to affected area once every 12 to 24 hours.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
Terminal half-life is approximately 7.5 hours (range 6-10 hours) in adults with normal hepatic function. This supports twined-daily dosing for dermatological indications.
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Primarily hepatic metabolism; metabolites excreted in urine and feces. Renal excretion of unchanged drug is negligible (<5%). Biliary/fecal excretion accounts for ~20% of metabolites.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic